Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,324 papers from all fields of science
Search
Sign In
Create Free Account
Bradykinin B2 Receptor Antagonists
Known as:
Bradykinin B2 Antagonists
, Antagonists, Bradykinin B2
, Bradykinin B2 Receptor Inhibitors
Expand
Compounds and drugs that inhibit ligand binding or cellular signaling by BRADYKININ B2 RECEPTORS.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
In Blood
aspects of radiation effects
chemical synthesis
standards characteristics
Narrower (1)
icatibant
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
A new series of highly potent non-peptide bradykinin B2 receptor antagonists incorporating the 4-heteroarylquinoline framework. Improvement of aqueous solubility and new insights into species…
Y. Sawada
,
H. Kayakiri
,
+9 authors
Hirokazu Tanaka
Journal of Medicinal Chemistry
2004
Corpus ID: 22295715
Introduction of nitrogen-containing heteroaromatic groups at the 4-position of the quinoline moiety of our non-peptide B(2…
Expand
1999
1999
Reduction of sodium deoxycholic acid‐induced scratching behaviour by bradykinin B2 receptor antagonists
I. Hayashi
,
M. Majima
British Journal of Pharmacology
1999
Corpus ID: 9850218
Subcutaneous injection of sodium deoxycholic acid into the anterior of the back of male ddY mice elicited dose‐dependent…
Expand
Review
1999
Review
1999
Discovery of orally active nonpeptide bradykinin B2 receptor antagonists.
M. Asano
,
N. Inamura
,
+7 authors
K. Nakahara
Immunopharmacology
1999
Corpus ID: 28062909
Highly Cited
1998
Highly Cited
1998
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.
Y. Abe
,
H. Kayakiri
,
+9 authors
Hirokazu Tanaka
Journal of Medicinal Chemistry
1998
Corpus ID: 31471801
Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor…
Expand
1998
1998
Activity of tachykinin NK1 and bradykinin B2 receptor antagonists, and an opioid ligand at different stimulation parameters in neurogenic inflammation in the rat
P. K. Towler
,
S. Brain
Neuroscience Letters
1998
Corpus ID: 26828767
1996
1996
Mechanisms of smokeless tobacco-induced oral mucosa inflammation: role of bradykinin.
X. Gao
,
J. Vishwanatha
,
J. Conlon
,
C. Olopade
,
I. Rubinstein
Journal of Immunology
1996
Corpus ID: 39964039
The purpose of this study was to determine whether an aqueous extract of smokeless tobacco (moist snuff) increases clearance of…
Expand
1996
1996
A new type of bradykinin B2 receptor antagonists: bradykinin analogs with N-alkyl amino acids at position 2.
S. Reissmann
,
G. Greiner
,
+7 authors
L. Gera
Immunopharmacology
1996
Corpus ID: 44395000
1995
1995
Ca2+‐dependent and ‐independent mechanism of cyclic‐AMP reduction: mediation by bradykinin B2 receptors
H. Sipma
,
A. Hertog
,
A. Nelemans
British Journal of Pharmacology
1995
Corpus ID: 22126092
1 Bradykinin caused a transient reduction of about 25% in the cyclic AMP level in forskolin prestimulated DDT1 MF‐2 smooth muscle…
Expand
1995
1995
The adenylate cyclase-inhibiting bradykinin receptor in guinea pig ileum membranes exhibits an unique antagonist profile.
C. Liebmann
,
A. Graness
,
A. Adomeit
,
S. Nawrath
European Journal of Pharmacology
1995
Corpus ID: 267728
Highly Cited
1994
Highly Cited
1994
Agonistic and antagonistic properties of the bradykinin B2 receptor antagonist, Hoe 140, in isolated blood vessels from different species
M. Félétou
,
M. Germain
,
C. Thurieau
,
J. Fauchère
,
E. Canet
British Journal of Pharmacology
1994
Corpus ID: 36088860
1 Hoe 140, a recently described bradykinin B2 antagonist, and NPC 567 from an earlier generation of bradykinin B2 antagonists…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE